Emergence of new ALK mutations at relapse of neuroblastoma.
about
The role of the ALK receptor in cancer biologyThe ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Protein glycosylation in cancers and its potential therapeutic applications in neuroblastomaEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Overview and recent advances in the treatment of neuroblastoma.Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Advances in Risk Classification and Treatment Strategies for Neuroblastoma.Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations.Relapsed neuroblastomas show frequent RAS-MAPK pathway mutationsGenetic changes of non-small cell lung cancer under neoadjuvant therapyThe ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNIdentification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Genetic discoveries and treatment advances in neuroblastoma.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroALK gene alterations in cancer: biological aspects and therapeutic implications.Mutational dynamics between primary and relapse neuroblastomas.The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding CloneAdvances in emerging drugs for the treatment of neuroblastoma.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma.Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.Diagnostic implications of intrapatient genetic tumor heterogeneity.Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.Precision medicine in pediatric oncology.A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.Patient-derived xenografts as preclinical neuroblastoma models.The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.ALK in Neuroblastoma: Biological and Therapeutic Implications.
P2860
Q26738384-787126B3-926B-4A53-81FA-04DB4E256F6FQ27853241-7975BCB4-351D-48F4-888A-AA709C61C7D6Q27853373-164E5448-5A66-4B75-B544-E588B7F314D5Q28069952-D4B71A9A-716E-4591-B158-A8F54D5BA777Q30234441-1C4AAC82-F6DC-405E-A1F9-DBF8772874B9Q30238693-228C309A-9F57-4DB0-90BC-044D8D4DF78AQ30239861-531ABC74-6DA0-43C8-9A0F-D52C750C0E75Q30384542-241D6304-849E-4632-AD61-55CA01332C22Q35469393-40FA5CE1-0F86-4E95-8A58-A5688CC6AA7DQ36053801-388BACC5-36EC-411F-9356-1BCB2D1A2ED2Q36229462-22092FCA-A25B-4B2A-B3DD-CE02C6798BC9Q36244760-0BDB5235-D854-4B16-B574-56313F934E65Q36641925-770663C2-FE50-42CD-8F77-935486E61DE3Q37301932-127DF258-4170-47B8-BBEF-E5D1F6968184Q37305906-9C263524-3DF9-4C77-8121-B22BB21B0130Q37699419-2A45C946-F484-43DE-9A85-48BFBC55F202Q38540135-A490DB29-F392-41E8-9397-B0ACE18A1B5DQ38616826-5D942EAD-A4BB-4EEF-B1B7-51F3233A1A19Q38623421-A56592DC-143D-4345-AA43-A239BFF1A795Q38625880-64C2DB33-1862-4C79-BE3E-5223EA3D6FDCQ38635551-067DACBF-DB25-4F7A-8F21-35FCD3B27EE9Q38730798-B8F1AC7E-6640-4AB9-9623-72AAF7FC11A9Q38767006-652DF23D-90B5-41AE-A841-6A71E80104CCQ38859077-1F991CD4-891B-4AB8-A181-81AE08D24C05Q38944495-23CD091F-182B-4FD0-A074-158825F055E2Q38947597-6511FC15-6D6B-4270-B454-E7CC3DB8749EQ39158415-E0E99238-D5B5-4553-9B3D-5D07071DB3F6Q40999620-A21C87D0-9DD7-4516-BE9D-7314EEF0EA7CQ41346041-FB1FD579-79C6-4AA6-BDCE-FE2290D494FAQ41840140-88CCF629-9980-4E79-8726-6792F774C17EQ42252770-6431ECA9-F52D-4814-9E10-60DF4333B957Q46874296-91245157-1894-49CA-A4F9-118CBA26624DQ47102779-1B4A8B9A-0E43-4576-B69B-43537FB72D2FQ47133403-4B66603E-0922-417E-978E-F81ECCD1D68AQ47135061-68F60E2C-7897-437A-BD26-69936D13FDE0Q47392557-F649B0C4-CE0F-49DD-9277-BC15DFCEE282Q49404911-79B53C59-F5BC-408E-A2CE-0A5764E88C63Q50027944-04992787-0CCD-4E13-894D-50313ED5BCC7Q51734147-25D9FCFA-91D9-4D9A-B2DA-618B4C7BCFA5Q52324760-CEA5D36D-1DE8-4F96-9F44-39EE47E51499
P2860
Emergence of new ALK mutations at relapse of neuroblastoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Emergence of new ALK mutations at relapse of neuroblastoma.
@en
type
label
Emergence of new ALK mutations at relapse of neuroblastoma.
@en
prefLabel
Emergence of new ALK mutations at relapse of neuroblastoma.
@en
P2093
P50
P356
P1476
Emergence of new ALK mutations at relapse of neuroblastoma.
@en
P2093
Britt-Marie Holmqvist
Catarina Träger
Eve Lapouble
Fredrik Hedborg
Gaelle Pierron
Gudrun Schleiermacher
Jean Michon
Julie Cappo
Michel Peuchmaur
P304
P356
10.1200/JCO.2013.54.0674
P407
P50
P577
2014-07-28T00:00:00Z